Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 16/20 | 0.42 |
| ▸ | RAF1 | P04049 | 4/20 | 0.42 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6805928 | 0.93 | BRAF (0.48) | BRAFRAF1 | |
| Hydrochloric Acid SCHEMBL6805992 | 0.92 | BRAF (0.48) | BRAFRAF1 | |
| SCHEMBL6805130 | 0.87 | KCNQ3 (0.54) | BRAFRAF1HTR1DHTR1BHTR2A | |
| SCHEMBL6805450 | 0.86 | GAA (0.41) | BRAFRAF1HTR1DHTR1BHTR2A | |
| SCHEMBL6806932 | 0.86 | KMT2A (0.49) | HTR1DHTR1BHTR2ANPC1POLB | |
| SCHEMBL7652847 | 0.85 | ROCK2 (0.46) | BRAFRAF1HTR1DHTR1BHTR2A | |
| SCHEMBL6805046 | 0.85 | NPC1 (0.51) | KCNQ3KCNQ2NPC1POLBRAB9A | |
| Hydrochloric Acid SCHEMBL6809944 | 0.85 | KMT2A (0.48) | HTR1DHTR1BHTR2ANPC1POLB | |
| SCHEMBL6805394 | 0.84 | MAPT (0.44) | BRAFRAF1HTR2AKCNQ3KCNQ2 | |
| Hydrochloric Acid SCHEMBL6805452 | 0.84 | NPC1 (0.50) | KCNQ3KCNQ2NPC1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1084122-B1 | TETRAHYDRONAPHTHYRIDINYL-CARBOXAMIDES HAVING ANTI-CONVULSANT ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2003-10-22 | — | — | EP | claimed |
| US-20020143029-A1 | Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity | SMITHKLINE BEECHAM P.L.C. | 2002-10-03 | — | — | US | claimed |
| US-6410555-B1 | ANTIEPILEPTIC AGENTS; HEADACHES | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-06-25 | — | — | US | claimed |
| EP-1084122-A1 | TETRAHYDRONAPHTHYRIDINYL-CARBOXAMIDES HAVING ANTI-CONVULSANT ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2001-03-21 | — | — | EP | claimed |
| WO-1999065903-A1 | TETRAHYDRONAPHTHYRIDINYL-CARBOXAMIDES HAVING ANTI-CONVULSANT ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1999-12-23 | — | — | WO | claimed |
| US-6762192-B2 | USEFUL IN THERAPY AND PROPHYLAXIS OF EPILEPSY, MIGRAINE, AND OTHER DISORDERS | SMITHKLINE BEECHUM P.L.C. (GB) | 2004-07-13 | — | — | US | disclosed |
| EP-1084122-B1 | TETRAHYDRONAPHTHYRIDINYL-CARBOXAMIDES HAVING ANTI-CONVULSANT ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2003-10-22 | — | — | EP | disclosed |
| US-20020143029-A1 | Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity | SMITHKLINE BEECHAM P.L.C. | 2002-10-03 | — | — | US | disclosed |
| US-6410555-B1 | ANTIEPILEPTIC AGENTS; HEADACHES | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-06-25 | — | — | US | disclosed |
| EP-1084122-A1 | TETRAHYDRONAPHTHYRIDINYL-CARBOXAMIDES HAVING ANTI-CONVULSANT ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999065903-A1 | TETRAHYDRONAPHTHYRIDINYL-CARBOXAMIDES HAVING ANTI-CONVULSANT ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143029-A1 | Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity | CNR1, SCN1B, CNR2 | BRAF 3791/4885RAF1 2568/4885HTR1D 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.